Why the study?
Does once-daily high-concentration nadroparin provide equivalent anti-Xa bioavailability compared to twice-daily standard-concentration nadroparin in healthy volunteers?
Population
12 healthy volunteers, age 18-35
Comparison
Nadroparin 20,500 anti-Xa IU/ml formulation, 180… vs Nadroparin 10,250 anti-Xa IU/ml formulation, 90…
Design
RCT, randomized, cross-over, open
Follow-up
10 days
Authors
Loading...
Supports once-daily high-concentration nadroparin for VTE treatment; extends evidence for simplified dosing regimens.
Does once-daily high-concentration nadroparin provide equivalent anti-Xa bioavailability compared to twice-daily standard-concentration nadroparin in healthy volunteers?
Once-daily administration of a more concentrated nadroparin formulation provides equivalent anti-Xa bioavailability to twice-daily administration of the standard formulation, supporting its use for venous thromboembolism treatment.
Navarro et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: